These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23363645)

  • 1. Reconsideration of anticoagulant therapy in Japanese patients with atrial fibrillation and moderate renal impairment.
    Shiga T
    Circ J; 2013; 77(3):596-7. PubMed ID: 23363645
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
    Hori M; Matsumoto M; Tanahashi N; Momomura S; Uchiyama S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iwamoto K; Tajiri M;
    Circ J; 2013; 77(3):632-8. PubMed ID: 23229461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban equals warfarin treatment in atrial fibrillation patients at high risk of stroke.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(6):342-3. PubMed ID: 21135986
    [No Abstract]   [Full Text] [Related]  

  • 4. Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: a subgroup analysis of J-ROCKET AF.
    Uchiyama S; Hori M; Matsumoto M; Tanahashi N; Momomura S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iekushi K; Yamanaka S; Tajiri M;
    J Stroke Cerebrovasc Dis; 2014; 23(5):1142-7. PubMed ID: 24189454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
    Hori M; Matsumoto M; Tanahashi N; Momomura S; Uchiyama S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iekushi K; Yamanaka S; Tajiri M;
    J Stroke Cerebrovasc Dis; 2014 Feb; 23(2):379-83. PubMed ID: 23954611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
    Mao L; Li C; Li T; Yuan K
    Vascular; 2014 Aug; 22(4):252-8. PubMed ID: 23929423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differential therapy with the new anticoagulants, 5].
    Stiefelhagen P
    MMW Fortschr Med; 2013 May; 155(9):20. PubMed ID: 23951642
    [No Abstract]   [Full Text] [Related]  

  • 8. Spontaneus splenic rupture in a patient treated with rivaroxaban.
    Gonzva J; Patricelli R; Lignac D
    Am J Emerg Med; 2014 Aug; 32(8):950.e3. PubMed ID: 24612597
    [No Abstract]   [Full Text] [Related]  

  • 9. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
    Martínez-Rubio A; Dan GA; Kaski JC
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angioedema due to the new oral anticoagulant rivaroxaban.
    Altin C; Ozturkeri OA; Gezmis E; Askin U
    Ann Card Anaesth; 2014; 17(2):173-4. PubMed ID: 24732626
    [No Abstract]   [Full Text] [Related]  

  • 11. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
    Ogawa S; Ikeda T; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iekushi K; Yamanaka S; Yamada T; Inuyama L;
    J Stroke Cerebrovasc Dis; 2014; 23(10):2520-2526. PubMed ID: 25245483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
    Paikin JS; Manolakos JJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):965-72. PubMed ID: 23030284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New anticoagulants in patients with atrial fibrillation].
    Diener HC; Weber R
    MMW Fortschr Med; 2013 May; 155(8):55-6, 58. PubMed ID: 24437140
    [No Abstract]   [Full Text] [Related]  

  • 14. [Stroke risk--atrial fibrillation].
    Dabitz R; Ochs G
    MMW Fortschr Med; 2012 Nov; 154(19):53-6. PubMed ID: 23173288
    [No Abstract]   [Full Text] [Related]  

  • 15. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
    Haas S; Bode C; Norrving B; Turpie AG
    Vasc Health Risk Manag; 2014; 10():101-14. PubMed ID: 24648742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
    Kosar L; Jin M; Kamrul R; Schuster B
    Can Fam Physician; 2012 Aug; 58(8):850-8. PubMed ID: 22893338
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New alternative to warfarin may help reduce stroke risk in patients with AF.
    Mitka M
    JAMA; 2011 Jan; 305(1):25-6. PubMed ID: 21205957
    [No Abstract]   [Full Text] [Related]  

  • 19. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2013 Feb; 11(2):129-41. PubMed ID: 23405833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Carter NJ; Plosker GL
    Drugs; 2013 May; 73(7):715-39. PubMed ID: 23677801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.